{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:08:33Z","timestamp":1789571313018,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100024157","name":"Neurelis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100024157","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40263-025-01198-0","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T23:03:14Z","timestamp":1751929394000},"page":"865-877","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety, Tolerability, and Pharmacokinetics of NRL-1049, a Rho-Associated Kinase Inhibitor, in Healthy Volunteers: A Phase 1, First-in-Human, Single-Ascending Dose, Randomized, Placebo-Controlled Trial"],"prefix":"10.1007","volume":"39","author":[{"given":"Stuart","family":"Madden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issam","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Lopez-Toledano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leock Y.","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Carrazana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian L.","family":"Rabinowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"1198_CR1","first-page":"1","volume":"4","author":"L Morrison","year":"2024","unstructured":"Morrison L, Gutierrez J, Ayata C, et al. Current and future treatment options for cerebral cavernous malformations. Stroke Vasc Interv Neurol. 2024;4:1\u201311.","journal-title":"Stroke Vasc Interv Neurol."},{"key":"1198_CR2","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1111\/ene.15253","volume":"29","author":"AN Santos","year":"2022","unstructured":"Santos AN, Rauschenbach L, Saban D, et al. Multiple cerebral cavernous malformations: clinical course of confirmed, assumed and non-familial disease. Eur J Neurol. 2022;29:1427\u201334.","journal-title":"Eur J Neurol"},{"key":"1198_CR3","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1161\/STROKEAHA.121.035338","volume":"53","author":"AN Santos","year":"2022","unstructured":"Santos AN, Rauschenbach L, Saban D, et al. Natural course of cerebral cavernous malformations in children: a five-year follow-up study. Stroke. 2022;53:817\u201324.","journal-title":"Stroke"},{"key":"1198_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3171\/2019.3.JNS181724","volume":"131","author":"IA Awad","year":"2019","unstructured":"Awad IA, Polster SP. Cavernous angiomas: deconstructing a neurosurgical disease. J Neurosurg. 2019;131:1\u201313.","journal-title":"J Neurosurg"},{"key":"1198_CR5","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/S1474-4422(15)00303-8","volume":"15","author":"MA Horne","year":"2016","unstructured":"Horne MA, Flemming KD, Su IC, et al. Clinical course of untreated cerebral cavernous malformations: a meta-analysis of individual patient data. Lancet Neurol. 2016;15:166\u201373.","journal-title":"Lancet Neurol"},{"key":"1198_CR6","first-page":"86","volume":"2","author":"MA Alonso-Vanegas","year":"2011","unstructured":"Alonso-Vanegas MA, Cisneros-Franco JM, Otsuki T. Surgical management of cavernous malformations presenting with drug-resistant epilepsy. Front Neurol. 2011;2:86.","journal-title":"Front Neurol"},{"key":"1198_CR7","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1212\/WNL.0b013e3182190f37","volume":"76","author":"CB Josephson","year":"2011","unstructured":"Josephson CB, Leach JP, Duncan R, et al. Seizure risk from cavernous or arteriovenous malformations: prospective population-based study. Neurology. 2011;76:1548\u201354.","journal-title":"Neurology"},{"key":"1198_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2595","volume":"12","author":"L Rauschenbach","year":"2022","unstructured":"Rauschenbach L, Bartsch P, Santos AN, et al. Quality of life and mood assessment in conservatively treated cavernous malformation-related epilepsy. Brain Behav. 2022;12: e2595.","journal-title":"Brain Behav"},{"key":"1198_CR9","doi-asserted-by":"crossref","unstructured":"Akers A, Al-Shahi Salman R, Awad I, et al. Guidelines for the clinical management of cerebral cavernous malformations: consensus recommendations based on systematic literature review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel. 2017. https:\/\/www.alliancetocure.org\/newly-diagnosed\/ccm-care-guidelines\/. Accessed Jul 3 2023.","DOI":"10.1093\/neuros\/nyx091"},{"key":"1198_CR10","unstructured":"US Food and Drug Administration. Orphan indications: 4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl. 2015. https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=487815. Accessed Apr 22 2025."},{"key":"1198_CR11","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000200121","volume":"10","author":"C Ayata","year":"2024","unstructured":"Ayata C, Kim H, Morrison L, et al. Role of rho-associated kinase in the pathophysiology of cerebral cavernous malformations. Neurol Genet. 2024;10: e200121.","journal-title":"Neurol Genet."},{"key":"1198_CR12","doi-asserted-by":"publisher","DOI":"10.4161\/sgtp.29846","volume":"5","author":"L Julian","year":"2014","unstructured":"Julian L, Olson MF. Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions. Small GTPases. 2014;5: e29846.","journal-title":"Small GTPases."},{"key":"1198_CR13","unstructured":"Kadmon Pharmaceuticals, LLC. REZUROK\u00ae (belumosudil). Full prescribing information. Bridgewater, NJ: Kadmon Pharmaceuticals, LLC; 2024."},{"key":"1198_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2147\/DDDT.S435522","volume":"18","author":"S Futterknecht","year":"2024","unstructured":"Futterknecht S, Chatzimichail E, Gugleta K, et al. The role of rho kinase inhibitors in corneal diseases. Drug Des Devel Ther. 2024;18:97\u2013108.","journal-title":"Drug Des Devel Ther."},{"key":"1198_CR15","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s12975-019-00725-8","volume":"11","author":"L McKerracher","year":"2020","unstructured":"McKerracher L, Shenkar R, Abbinanti M, et al. A brain-targeted orally available ROCK2 inhibitor benefits mild and aggressive cavernous angioma disease. Transl Stroke Res. 2020;11:365\u201376.","journal-title":"Transl Stroke Res"},{"key":"1198_CR16","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1177\/0271678X241238845","volume":"44","author":"IA Mulder","year":"2024","unstructured":"Mulder IA, Abbinanti M, Woller SA, et al. The novel ROCK2 selective inhibitor NRL-1049 preserves the blood-brain barrier after acute injury. J Cereb Blood Flow Metab. 2024;44:1238\u201352.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1198_CR17","unstructured":"United States Food and Drug Adminisration. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers; 2005."},{"key":"1198_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7:27\u201331.","journal-title":"J Basic Clin Pharm."},{"key":"1198_CR19","unstructured":"Rosen KM, Abbinanti MD, Ruschel J, et al., inventors; BioAxone BioSciences, Inc., assignee. Rho Kinase Inhibitor BA-1049 (R) and Actie Metabolites Thereof. US Patent Patent 10,106,525 B2. 2018."},{"key":"1198_CR20","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s10456-021-09809-2","volume":"24","author":"DR Vannier","year":"2021","unstructured":"Vannier DR, Shapeti A, Chuffart F, et al. CCM2-deficient endothelial cells undergo a ROCK-dependent reprogramming into senescence-associated secretory phenotype. Angiogenesis. 2021;24:843\u201360.","journal-title":"Angiogenesis"},{"key":"1198_CR21","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.216093","volume":"131","author":"J Lisowska","year":"2018","unstructured":"Lisowska J, Rodel CJ, Manet S, et al. The CCM1-CCM2 complex controls complementary functions of ROCK1 and ROCK2 that are required for endothelial integrity. J Cell Sci. 2018;131: jcs216093.","journal-title":"J Cell Sci"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01198-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01198-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01198-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T01:32:40Z","timestamp":1757208760000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01198-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1198"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01198-0","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"2 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Neurelis, Inc. (San Diego, California). Open access was funded by Neurelis, Inc. (San Diego, California).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"S.M. is an employee of and has received stock and stock options from Neurelis, Inc. I.A. is a consultant to Neurelis, Inc.; is chairman (unpaid) of the scientific advisory board for the Alliance to Cure Cavernous Malformation; and receives research support from the National Institute of Neurological Disorders and Stroke. M.A.L.T. is an employee of and has received stock options from Neurelis, Inc. L.M. is a consultant to Neurelis, Inc. J.G. was, at the time of this study, an employee of and has received stock options from Neurelis, Inc. L.Y.N. is an employee of and has received stock options from Neurelis, Inc. E.C. is an employee of and has received stock and stock options from Neurelis, Inc. A.L.R. is an employee of and has received stock options from Neurelis, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All data are included in the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The study protocol, informed consent, and all other study documents were approved by an institutional review board (Advarra; protocol number, Pro00068446). The study was conducted in accordance with the Declaration of Helsinki, the International Council for Harmonisation, Guideline E6 for Good Clinical Practice (GCP), the Food and Drug Administration GCP Code of Federal Regulations Title 21 (part 56), the European regulation EU 536\/2014, and the Tri-Council Policy Statement (Canada).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written consent was obtained from each participant prior to study enrollment.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"S.M., M.A.L.T., J.G., E.C., and A.L.R. were involved in the conception and design of the study, as well as data analysis. All authors were involved in data interpretation, review of literature, and drafting of the manuscript. All authors critically reviewed and revised the work, and all read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}